Impact of the cyp2d6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers / Julia Kirchheiner en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 6 (Diciembre) . - pp. 647-652 Título : Impact of the cyp2d6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers Tipo de documento: texto impreso Autores: Julia Kirchheiner, Autor ; Hanns Benjamin Henckel, Autor ; Ingolf Meineke, Autor Fecha de publicación: 2023 Artículo en la página: pp. 647-652 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Intervalos de confianza, Citocromo P-450 CYP2D6, Frecuencia genética, Tasa de aclaramiento metabólico, Mianserina. Resumen: In vitro studies showed that biotransformation of the antidepressant drug mirtazapine is mediated by cytochrome P-450 enzymes CYP1A2, CYP2D6, and CYP3A4 with CYP2D6 contributing about 35% to total mirtazapine biotransformation. We hypothesized that ultrarapid metabolizers (defined as carriers of the CYP2D6 gene duplication plus another functional allele) have a risk for therapeutic failure due to too low tissue concentrations. Link: ./index.php?lvl=notice_display&id=30939 [artículo] Impact of the cyp2d6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers [texto impreso] / Julia Kirchheiner, Autor ; Hanns Benjamin Henckel, Autor ; Ingolf Meineke, Autor . - 2023 . - pp. 647-652. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 6 (Diciembre) . - pp. 647-652 Palabras clave: Intervalos de confianza, Citocromo P-450 CYP2D6, Frecuencia genética, Tasa de aclaramiento metabólico, Mianserina. Resumen: In vitro studies showed that biotransformation of the antidepressant drug mirtazapine is mediated by cytochrome P-450 enzymes CYP1A2, CYP2D6, and CYP3A4 with CYP2D6 contributing about 35% to total mirtazapine biotransformation. We hypothesized that ultrarapid metabolizers (defined as carriers of the CYP2D6 gene duplication plus another functional allele) have a risk for therapeutic failure due to too low tissue concentrations. Link: ./index.php?lvl=notice_display&id=30939

---

1 (1 - 1 / 1)